![ImaRx Therapeutics, Inc. logo](/news-release/logo/215055/0/215055.jpg?lastModified=12%2F10%2F2016%2002%3A14%3A23&size=2)
ImaRx Therapeutics Reports Second Quarter Ended 2009 Financial Results
11 août 2009 07h00 HE
|
ImaRx Therapeutics, Inc.
REDMOND, Wash., Aug. 11, 2009 (GLOBE NEWSWIRE) -- ImaRx Therapeutics, Inc. (OTCBB:IMRX), a development-stage biopharmaceutical company, whose research and development efforts have focused on the...
![ImaRx Therapeutics, Inc. logo](/news-release/logo/215055/0/215055.jpg?lastModified=12%2F10%2F2016%2002%3A14%3A23&size=2)
ImaRx Therapeutics Reports First Quarter Ended 2009 Financial Results
14 mai 2009 16h30 HE
|
ImaRx Therapeutics, Inc.
REDMOND, Wash., May 14, 2009 (GLOBE NEWSWIRE) -- ImaRx Therapeutics, Inc. (OTCBB:IMRX), a development-stage biopharmaceutical company focused on the development of new treatments for vascular...
![ImaRx Therapeutics, Inc. logo](/news-release/logo/215055/0/215055.jpg?lastModified=12%2F10%2F2016%2002%3A14%3A23&size=2)
ImaRx Therapeutics Reports Fourth Quarter and Year Ended 2008 Financial Results
06 mars 2009 18h00 HE
|
ImaRx Therapeutics, Inc.
REDMOND, Wash., March 6, 2009 (GLOBE NEWSWIRE) -- ImaRx Therapeutics, Inc. (OTCBB:IMRX), a biopharmaceutical company focused on the development of new treatments for vascular disorders leveraging its...
![ImaRx Therapeutics, Inc. logo](/news-release/logo/215055/0/215055.jpg?lastModified=12%2F10%2F2016%2002%3A14%3A23&size=2)
ImaRx Therapeutics Reports Third Quarter Ended 2008 Financial Results
13 nov. 2008 08h00 HE
|
ImaRx Therapeutics, Inc.
TUCSON, Ariz., Nov. 13, 2008 (GLOBE NEWSWIRE) -- ImaRx Therapeutics, Inc. (OTCBB:IMRX), a biopharmaceutical company focused on the development of new treatments for vascular disorders leveraging its...
![ImaRx Therapeutics, Inc. logo](/news-release/logo/215055/0/215055.jpg?lastModified=12%2F10%2F2016%2002%3A14%3A23&size=2)
ImaRx Therapeutics Receives NASDAQ Delisting Notification
17 oct. 2008 07h00 HE
|
ImaRx Therapeutics, Inc.
TUCSON, Ariz., Oct. 17, 2008 (GLOBE NEWSWIRE) -- ImaRx Therapeutics, Inc. (Nasdaq:IMRX) today announced that it has been advised by The Nasdaq Stock Market ("NASDAQ") pursuant to Marketplace Rule 4300...
![ImaRx Therapeutics, Inc. logo](/news-release/logo/215055/0/215055.jpg?lastModified=12%2F10%2F2016%2002%3A14%3A23&size=2)
ImaRx Therapeutics Divests Urokinase Franchise to Microbix Biosystems
24 sept. 2008 06h00 HE
|
ImaRx Therapeutics, Inc.
TUCSON, Ariz., Sept. 24, 2008 (GLOBE NEWSWIRE) -- ImaRx Therapeutics, Inc. (Nasdaq:IMRX) today announced that it has divested its urokinase business to Microbix Biosystems, Inc. (TSX:MBX). Through...
![ImaRx Therapeutics, Inc. logo](/news-release/logo/215055/0/215055.jpg?lastModified=12%2F10%2F2016%2002%3A14%3A23&size=2)
ImaRx Therapeutics Receives Notification From NASDAQ Regarding Non-Compliance With NASDAQ's Stockholders' Equity, Market Value, or Net Income Requirements
26 août 2008 17h00 HE
|
ImaRx Therapeutics, Inc.
TUCSON, Ariz., Aug. 26, 2008 (GLOBE NEWSWIRE) -- ImaRx Therapeutics, Inc. (Nasdaq:IMRX) today announced that it received a NASDAQ Staff Deficiency Letter on August 20, 2008 indicating, based on the...
![ImaRx Therapeutics, Inc. logo](/news-release/logo/215055/0/215055.jpg?lastModified=12%2F10%2F2016%2002%3A14%3A23&size=2)
ImaRx Therapeutics Reports Second Quarter Ended 2008 Financial Results
14 août 2008 16h00 HE
|
ImaRx Therapeutics, Inc.
TUCSON, Ariz., Aug. 14, 2008 (PRIME NEWSWIRE) -- ImaRx Therapeutics, Inc. (Nasdaq:IMRX), a biopharmaceutical company with a commercial product, urokinase, and a research and development program...
![ImaRx Therapeutics, Inc. logo](/news-release/logo/215055/0/215055.jpg?lastModified=12%2F10%2F2016%2002%3A14%3A23&size=2)
ImaRx's Clot Dissolving Technology Being Presented at the AHA Conference
04 nov. 2004 08h30 HE
|
ImaRx Therapeutics, Inc.
TUCSON, Ariz., Nov. 4, 2004 (PRIMEZONE) -- ImaRx Therapeutics, Inc. (www.imarx.com) is pleased to announce that Jeane M. Tsutsui, MD of the University of Nebraska Medical Center will be presenting...
![ImaRx Therapeutics, Inc. logo](/news-release/logo/215055/0/215055.jpg?lastModified=12%2F10%2F2016%2002%3A14%3A23&size=2)
ImaRx Top Scientist Granted Excellence in Biotechnology Award for Outstanding Achievement in Drug Delivery
01 nov. 2004 08h30 HE
|
ImaRx Therapeutics, Inc.
TUCSON, Ariz., Nov. 1, 2004 (PRIMEZONE) -- Terry Matsunaga, PharmD, Ph.D., Vice President of Research for ImaRx Therapeutics, Inc. (www.imarx.com) received the Excellence in Biotechnology Award for...